Overview

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

Status:
Recruiting
Trial end date:
2023-03-02
Target enrollment:
Participant gender:
Summary
This is a single center study to assess the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma in China.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Immunochina Medical Science & Technology Co., Ltd.